Preparation and characterization of an anti-inflammatory agent based on a zinc-layered hydroxide-salicylate nanohybrid and its effect on viability of Vero-3 cells

Munirah Ramli1,2
Mohd Zobir Hussein1,3
Khatijah Yusoff4
1 Advanced Materials and Nanotechnology Laboratory, Institute of Advanced Technology, Universiti Putra Malaysia, Serdang, Selangor, 2 Department of Industrial Biotechnology, Faculty of Biosciences and Bioengineering, Universiti Teknologi Malaysia, Skudai, Johor, 3 Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, 4 Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Abstract: A new organic-inorganic nanohybrid based on zinc-layered hydroxide intercalated with an anti-inflammatory agent was synthesized through direct reaction of salicylic acid at various concentrations with commercially available zinc oxide. The basal spacing of the pure phase nanohybrid was 15.73 Å, with the salicylate anions arranged in a monolayer form and an angle of 57 degrees between the zinc-layered hydroxide interlayers. Fourier transform infrared study further confirmed intercalation of salicylate into the interlayers of zinc-layered hydroxide. The loading of salicylate in the nanohybrid was estimated to be around 29.66%, and the nanohybrid exhibited the properties of a mesoporous-type material, with greatly enhanced thermal stability of the salicylate compared with its free counterpart. In vitro cytotoxicity assay revealed that free salicylic acid, pure zinc oxide, and the nanohybrid have a mild effect on viability of African green monkey kidney (Vero-3) cells.

Keywords: anti-inflammatory, salicylic acid, zinc-layered hydroxide, zinc oxide, nanohybrid, cytotoxicity

Introduction
Development of drug delivery systems that can effectively elicit the intended therapeutic effect in patients with minimal adverse reactions has been widely explored in recent years. This research was mainly catalyzed by the challenges in attaining satisfactory pharmacokinetic profiles using conventional drug administration methods.1 The emergence of nanomedicine, a convergence between nanoscience and medicine, has markedly potentiated the revolution in delivery of therapeutic compounds through fabrication of ingenious nanovehicles.2–6

Application of inorganic nanoparticles in drug delivery systems has garnered considerable attention because they possess versatile attributes, including wide availability, good biocompatibility, and rich surface functionality.4 Targeted delivery of a drug molecule to the desired site of action is also made achievable by use of nanoparticles as carriers, which has been found to be exceptionally beneficial in studies involving delivery of chemotherapeutic agents in cancer therapy.7 In addition, nanoparticle-based drug delivery systems can slowly release the carried drugs in order to maintain concentrations at the desired levels for an extended period of time.8 To date, a multitude of inorganic nanoparticles has been extensively employed in drug delivery studies, including iron oxide,9,10 silica nanoparticles,11 calcium phosphate or hydroxyapatite,12,13
gold nanoparticles, carbon nanotubes, dendrimers, layered double hydroxides, and quantum dots.

Layered double hydroxides (LDHs) are regarded as promising drug delivery carriers because of several notable characteristics. In addition to ease of laboratory preparation and precise tailoring for the required physical and chemical properties, LDHs can be versatile carriers because various drugs can be intercalated into the interlayer spacing through ion exchange, and their degradation in an acidic cellular environment liberates the carried drugs in their ionic form, which helps improve their solubility and bioavailability. Improved cellular uptake of the drug-LDH nanohybrid has been reported, possibly because of its high zeta potential that provides a strong driving force to the surface of a cell. LDHs are also excellent candidates for drug delivery systems because they possess good biocompatibility and low cytotoxicity.

LDHs are hydrotalcite-like materials that can be readily synthesized through introduction of a suitable mixture of metal salts. The structure of the LDH is based on individual layers of metal cations octahedrally arranged with hydroxide groups, in which each hydroxide is surrounded by three metal cations, creating neutral layers. Isomorphic replacement of divalent cations with trivalent cations creates an excess of charge in the layers, which is neutralized by the interlayer anions. It can be represented by the general hydrotalcite formula, \( [M_2^{x+} \cdot M_3^{y+} (OH)_z]^n (A^{m-})_m \cdot nH_2O \), where \( M_2^{x+} \) is divalent cations, \( M_3^{y+} \) is trivalent cations, and \( A^{m-} \) is an exchangeable anion with an \( m- \) charge. Zinc-layered hydroxide (ZLH) is another type of material made up of brucite-like layers. The layers are modified such that one quarter of the octahedral sites are vacant. Tetrahedrally coordinated zinc cations are located at the up and down side of the vacant octahedra, while the tetrahedra are formed by three hydroxide groups of the brucite-like layers and a water molecule. The structure can be represented by the general formula \( M_2^{x+} (OH)_z (A^{m-})_m \cdot nH_2O \), where \( M_2^{x+} \) is the \( Zn^{2+} \) and \( A^{m-} \) is the counter anion with an \( m^{-} \) charge.

Similar to LDH, the use of ZLH as a potential delivery vector is currently being studied extensively. Many successful intercalations have been reported with various therapeutic compounds, including conjugated linoleic acid, indole-3-acetic acid, gallic acid, ascorbic acid, retinoic acid, and \( \alpha \)-tocopherol.

Saliacylic acid, also known as 2-hydroxybenzoic acid, is a nonsteroidal anti-inflammatory agent commonly used in the treatment of arthritis. Its use is often associated with adverse effects, including formation of gastric and duodenal ulcers, so developing a carrier that might alleviate such effects is desirable. Intercalation of salicylate into different LDH has previously been reported, but no report on the use of ZLH as the carrier could be found in the literature. In addition, very little information is available on the use of zinc oxide (ZnO) as the starting material for synthesis of a drug-intercalated nanohybrid. Therefore, to illustrate the use of ZnO for intercalation of organic compounds with therapeutic effects, this study focused on the formation of a nanohybrid compound consisting of an anti-inflammatory active agent, salicylate, and using ZnO as the starting material. The synthesized nanohybrid was later subjected to a cytotoxicity study using in vitro cells.

**Materials and methods**

**Materials**

Salicylic acid (98% purity) was purchased from HmbG Chemicals (Hamburg, Germany) and used as received. ZnO of American Chemical Society Standard reagent grade was purchased from Acros Organics (Geel, Belgium) and used without further purification. Deionized water and ethanol were used in all experiments. Dulbecco’s modified Eagle’s medium was purchased from PAA Laboratories (Pasching, Austria), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-razosodium bromide (MTT) from Invitrogen (Carlsbad, CA), and used as received. Dimethylsulfoxide of tissue culture grade was purchased from Sigma-Aldrich (St Louis, MO) and used without further purification.

**Preparation of salicylate nanohybrids**

Salicylate-zinc layered hydroxide nanohybrids (SZNs) were synthesized using ZnO as the starting material by a direct method reported previously. Salicylic acid solution (0.1–1.6 mol/L) was prepared by dissolving the appropriate amount of salicylic acid in ethanol, followed by stirring at ambient temperature for 10 minutes. ZnO (0.2 g) was mixed with the solution of salicylic acid and stirred vigorously until the solution became clear. The pH was adjusted to 8.0 using an aqueous solution of NaOH (1.0 mol/L) and vigorously stirred further for 4 hours at ambient temperature. The resulting white precipitate was matured at 70 °C in an oil bath shaker for 18 hours. The precipitate was centrifuged and washed thoroughly with deionized water and dried in an oven at 60 °C. The powdered material was stored in a sample bottle placed in a container with dessicant for further use and characterization.

**Characterization**

Powder X-ray diffraction patterns were recorded at 2–60 degrees on a diffractometer (XRD-6000, Shimadzu,
Tokyo, Japan) using CuKα radiation at 40 kV and 30 mA. Fourier transform infrared (FTIR) spectra of the materials were recorded over the range of 400–4000 cm⁻¹ on an FTIR spectrophotometer (1725X, Perkin-Elmer, Waltham, MA) using a KBr disc method. Analysis of carbon, hydrogen, nitrogen, and sulfur (CHNS) content in the materials was performed using a Leco model CHNS-932 analyzer (St Joseph, MI), while elemental analysis was performed using inductively-coupled plasma atomic emission spectroscopy (Optima 2000DV, Perkin-Elmer). Thermogravimetric and differential thermogravimetric analysis (TGA-DTG) was carried out using a thermogravimetric analyzer (Mettler Toledo, Greifensee, Switzerland). Surface characterization of the materials was done using a nitrogen gas adsorption-desorption technique at 77 K (ASAP 2000, Micromeritics, Norcross, GA). The surface morphology of the materials was observed using a field emission scanning electron microscope (Nova NanoSEM 230, Hillsboro, OR).

**MTT cytotoxicity assay**

The cytotoxicity of the synthesized material was determined using the MTT assay. African green monkey kidney (Vero-3) cells were grown in Dulbecco’s modified Eagle medium supplemented with 10% fetal bovine serum at 37°C with 5% CO₂.

---

**Figure 1** Powder X-ray diffraction patterns for zinc oxide and SZN prepared at various concentrations of salicylic acid.

**Note:** () indicates unknown peak generated by the diffractometer.

**Abbreviation:** SZN, salicylate-zinc layered hydroxide nanohybrid.
The cells ($5 \times 10^4$ cells/mL) were seeded into a 96-well plate and incubated for 24 hours at 37°C with 5% CO$_2$. Test samples were diluted in Dulbecco’s modified Eagle’s medium and 200 µL was added into each well. After 48 hours of incubation, MTT reagent (0.5 mg/mL) in phosphate-buffered saline was added into each well and incubated further for 4 hours at 37°C. The MTT solution was removed, and 100 µL of dimethylsulfoxide was added into each well in order to dissolve formazan crystals. The plate was then analyzed under a microtiter plate reader at 570 nm.

**Results and discussion**

**X-ray diffraction**

Figure 1 shows the diffraction patterns of SZN synthesized using various concentrations of salicylic acid (0.1–1.6 mol/L). For ZnO, five intense reflections at 30–60 degrees corresponded to diffractions of 100, 002, 101, 102, and 110 planes, all of which are typical of ZnO. The diffraction patterns also revealed that the solid had good crystallinity. Intercalation of anions within the interlayer spacing of ZLH would result in an increment in the basal spacing because of displacement of exchangeable interlayer anions. Inclusion of anions in the ZLH interlayers was also reflected by the presence of peaks at a lower 2θ value, as shown in the diffraction patterns of the SZN nanohybrid. The basal spacing was recorded at 15.78 Å, 15.95 Å, 15.73 Å, and 15.98 Å for 0.2 mol/L, 0.4 mol/L, 0.8 mol/L, and 1.6 mol/L salicylic acid, respectively. Disappearance of the intense ZnO peaks also indicated that the solid was successfully converted into ZLH. No intercalation took place using 0.1 mol/L salicylic acid.

Comparison of the powder X-ray diffraction patterns showed that SZN synthesized using 0.8 mol/L salicylic acid was of relatively purer phase. In contrast, the other three nanohybrids still contained ZnO phase, with SZN synthesized using 0.2 mol/L salicylic acid exhibiting the highest ZnO intensity. Therefore, the former purer-phase nanohybrid was used for further analysis and labeled as SZN 0.8 mol/L. Formation of a pure-phase nanohybrid could possibly be hampered by use of nonuniform granular-structured ZnO particles (Figure 6A). It is postulated that the larger ZnO particles hindered complete intercalation taking place over a given period of reaction time, thereby resulting in the remainder, ie, unreacted ZnO phase. The formation of SZN is believed to have occurred through a dissociation-deposition mechanism. In aqueous conditions, ZnO hydrolyzed into Zn(OH)$_2$ on the surface of the solid particle. The resulting Zn(OH)$_2$ then dissociated at the solution-solid interface to form Zn$^{2+}$ species, which then reacted with hydroxyls, salicylate anions, and water in solution to generate the layered SZN nanohybrid compound.

Intercalation of salicylate organic moieties into the interlayer spaces between the metal hydroxide layers resulted in an expansion of the basal spacing, caused by a larger molecular size of salicylate as well as the spatial arrangement of the anions in the intergallery space. Figure 2A shows the three-dimensional size of salicylic acid, as estimated by Chemoffice Ultra 2008 software (Cambridge, MA). The long and short axes and molecular thickness of salicylic acid are 8.4 Å, 6.9 Å, and 2.8 Å, respectively (Figure 2A). Subtracting the thickness of the ZLH inorganic layer (4.8 Å)$^{36,45}$ and the zinc tetrahedra (2.6 Å each)$^{46}$ from the d-spacing of SZN obtained from the

![Figure 2](image-url) Molecular structure and three-dimensional molecular size of salicylic acid (A) and spatial orientation of salicylate anions in the inorganic interlayers of salicylate-zinc layered hydroxide (ZLH) nanohybrid (B).
powder X-ray diffraction spectrum (15.73 Å), the gallery height available for salicylate occupation was 5.73 Å. Because this value was smaller than the dimension of salicylic acid along the y axis and x axis, and bigger than the thickness of two molecules of salicylic acid, the most plausible arrangement is when salicylate anions are arranged as a monolayer with an angle of 57 degrees between the ZLH interlayers, with the carboxylate groups positioned towards the ZLH layers (Figure 2B).

**FTIR spectroscopy and elemental analysis**

FTIR spectra for ZnO, salicylic acid, and the SZN 0.8 mol/L nanohybrid are shown in Figure 3. The FTIR spectrum for pure ZnO (Figure 3A) displays a characteristic peak at 373 cm\(^{-1}\), attributable to the vibration of the zinc and oxygen sublattices.\(^7\) The FTIR spectrum for pure salicylic acid in Figure 3B shows a broad absorption band that spreads from 3229 cm\(^{-1}\) to 2591 cm\(^{-1}\), which can be attributed to the O–H stretching vibration.\(^8\) The band at 1656 cm\(^{-1}\) corresponds to the carbonyl group, while those at 1608 cm\(^{-1}\) and 1439 cm\(^{-1}\) refer to the C–C stretching of the aromatic ring.\(^9\) The bands caused by C–O and O–H vibration were recorded at 1291 cm\(^{-1}\) and 1236 cm\(^{-1}\), respectively.\(^10\)

The FTIR spectra for the SZN 0.8 mol/L nanohybrid in Figure 3C illustrates bands characteristic of pure salicylic acid.

![Figure 3](image-url)
indicating successful intercalation of the guest anions into the ZLH interlayers. However, the band attributable to C=O vibration of the acid has vanished because salicylic acid is intercalated in the anionic form. In turn, intense bands developed at 1566 cm\(^{-1}\), 1453 cm\(^{-1}\), and 1348 cm\(^{-1}\), which can be attributed to the asymmetric and symmetric carboxylate stretching mode of the salicylate anions.

Successful intercalation of salicylate into ZLH was further supported by CHNS analysis, as shown in Table 1. The SZN 0.8 mol/L nanohybrid contained 18.04% carbon (w/w) and 2.09% hydrogen (w/w), and no nitrogen was present in the sample. The loading percentage of salicylate in the nanohybrid was 29.66% (w/w) and analysis using inductively-coupled plasma atomic emission spectroscopy showed that SZN 0.8 mol/L contained 56.65% zinc (w/w).

### Table 1 Physicochemical properties of ZnO and SZN 0.8 mol/L

<table>
<thead>
<tr>
<th>Sample</th>
<th>C (%)</th>
<th>H (%)</th>
<th>N (%)</th>
<th>Zn (% w/w)</th>
<th>Anion (% w/w)</th>
<th>BET surface area (m(^2)/g)</th>
<th>BJH pore volume (cm(^3)/g)</th>
<th>BJH pore diameter (Å)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZnO</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(80.31)</td>
<td>–</td>
<td>4</td>
<td>0.03</td>
<td>17</td>
</tr>
<tr>
<td>SZN 0.8 mol/L</td>
<td>18.04</td>
<td>2.09</td>
<td>–</td>
<td>–</td>
<td>56.65(a)</td>
<td>29.66(a)</td>
<td>49</td>
<td>153</td>
</tr>
</tbody>
</table>

Notes: Values in parentheses are theoretical values; \(a\) Estimated from CHNS analysis; \(b\) Estimated from inductively coupled plasma analysis.

Abbreviations: ZnO, zinc oxide; SZN, salicylate-zinc layered hydroxide nanohybrid; BJH, Barrett-Joyner-Halenda; BET, Brunauer-Emmett-Teller.

### Thermal analysis

The TGA-DTG analysis obtained for salicylic acid and SZN 0.8 mol/L is shown in Figure 4. The TGA-DTG thermograms for free salicylic acid (Figure 4A) show a single stage of weight loss at a temperature maxima of 142.8°C, which can be attributed to complete combustion of the pure salicylic acid (99.5%). Meanwhile, the thermal behavior of the SZN 0.8 mol/L nanohybrid shows three stages of weight loss between 40.4°C and 491.0°C (Figure 4B). The first stage of weight loss between 40.4°C and 91.5°C is attributed to removal of surface-physiosorbed water molecules,\(41,43\) with an 8.4% weight loss. A second band corresponding to intercalated water molecules was not detected during this stage of weight loss, which is further affirmed by the absence of an absorption band at 1600 cm\(^{-1}\) in the FTIR.\(40\) This phenomenon was taken into account during the structural modeling exercise described earlier. The other stages of weight loss are characterized by dehydroxylation of the hydroxide layers and decomposition of the organic moieties, ie, salicylate anions.\(51\)

The stages between 179.8°C and 491.0°C accounted for a total weight loss of 42.3%. It is worth noting that decomposition of the intercalated salicylate occurred at a notably higher temperature than that of free salicylic acid, indicating that the thermal stability of salicylate in SZN 0.8 mol/L is enhanced because of the interaction between salicylate anions and the host, ZLH.

### Surface properties and surface morphology

Figure 5 shows the adsorption-desorption isotherms for ZnO and SZN 0.8 mol/L. As shown in Figure 5A, the adsorption-desorption isotherm for ZnO is categorized as...
The uptake of adsorbate occurred slowly at low relative pressure in the range of 0.0–0.9, followed by rapid adsorption from 0.9 onwards until an optimum adsorption of approximately 25 cm$^3$/g was achieved. The isotherm of SZN-0.8 mol/L also showed the surface properties of the type IV isotherm. Adsorption occurred in a gradually increasing manner from the relative pressure of 0.0 to 0.8. At 0.8, rapid adsorption ensued, until optimum adsorption took place at a higher relative pressure. The optimum uptake was recorded at 290 cm$^3$/g, which was 12-fold higher than that of ZnO. The desorption branch of the hysteresis loop for ZnO was much narrower than that of SZN 0.8 mol/L, indicating that both materials possessed different pore textures. The surface area of both materials as determined by the Brunauer-Emmett-Teller method is shown in Table 1. As a result of intercalation, the surface area increased from 4 m$^2$/g for ZnO to 49 m$^2$/g for SZN 0.8 mol/L.

Figure 5B illustrates the Barrett-Joyner-Halenda pore size distribution plots for ZnO and SZN 0.8 mol/L. The pore distribution of ZnO exhibited a peak centered at 32 Å, while SZN 0.8 mol/L showed an intense peak at approximately 154 Å. The pore volume and diameter for ZnO and SZN 0.8 mol/L are tabulated in Table 1. The pore volume increased from 0.03 cm$^3$/g to 0.44 cm$^3$/g for ZnO and SZN 0.8 mol/L.

Figure 6 illustrates the field emission scanning electron microscopic images of (A) zinc oxide with 50,000 × magnification and (B) salicylate-zinc layered hydroxide nanohybrid 0.8 mol/L with 100,000 × magnification.

Figure 5 Adsorption-desorption isotherms (A) and Barrett-Joyner-Halenda pore size distribution (B) for ZnO and SZN 0.8 mol/L.

Abbreviations: ZnO, zinc oxide; SZN, salicylate-zinc layered hydroxide nanohybrid.
respectively, while the pore diameter increased from 17 Å to 153 Å after salicylate was intercalated into the interlayer spacing of ZLH.

The surface morphology of ZnO and the SZN 0.8 mol/L nanohybrid, examined using field emission scanning electron microscopy, is illustrated in Figure 6. ZnO was revealed as having a nonuniform granular structure, without any specific shape. The material existed in various sizes and shapes (Figure 6A). After intercalation of salicylate, this structure was transformed into an agglomerate, consisting of curled-up sheet like structures, the particle size of which was markedly reduced in comparison with the starting material, ZnO (Figure 6B). This shows that inclusion of salicylate into the interlayer spacing of ZLH resulted in a change in the surface morphology, in which an irregular granular structure was converted into more uniform rolled-up sheets.

**MTT cytotoxicity test**

The effect of free salicylic acid, ZnO, and the SZN 0.8 mol/L nanohybrid on the viability of Vero-3 cells is shown in Figure 7. The cytotoxicity test was performed using an MTT assay, in which the ability of metabolically active cells to convert yellow MTT reagent into purple formazan by chemical reduction of the mitochondrial reductase enzyme is measured. As shown in Figure 7, viability of the Vero-3 cells decreased as the concentration of the test materials increased. All materials were mildly toxic towards Vero-3 cells, resulting in up to 35% cell mortality even at the highest dosage used (25 µg/mL). Interestingly, pure ZnO was found to be the least toxic compared with free salicylic acid and the SZN 0.8 mmol/L nanohybrid, with 92% viability calculated using 25 µg/mL ZnO. On the other hand, both free salicylic acid and the SZN 0.8 mol/L nanohybrid were found to have a similar effect on the viability of Vero-3 cells. However, at higher concentrations (12.5 µg/mL and 25 µg/mL), the latter was more toxic to the Vero-3 cells, with viability at 80% and 73%, respectively.

Although all the materials were generally nontoxic, a conclusive effect of concentration on cell viability was regrettably not established in this experiment. The concentrations employed were unable to elicit a more widespread effect on the cells, thereby preventing determination of an IC₅₀ value for each of the test materials. The cells probably needed to be exposed to higher concentrations of the test materials or subjected to a prolonged duration of exposure in order to obtain more comprehensive information on the effect of the test materials on cell viability. Such information is needed before a transfection study entailing investigation.
of the effects of the nanohybrid at a molecular level can be carried out.

**Conclusion**

A new nanohybrid compound based on salicylate-intercalated ZLH was synthesized via a simple direct reaction of pure ZnO with salicylic acid solution. The pure-phase nanohybrid was obtained using 0.8 mol/L salicylic acid, and the basal spacing was recorded at 15.73 Å. FTIR analysis showed that the nanohybrid possesses the absorption characteristics of both ZnO and free salicylic acid, while elemental analysis showed that the nanohybrid contained 29.66% (w/w) salicylate. In addition, intercalation of salicylate into the interlayers of ZLH had enhanced thermal stability in comparison with free salicylic acid. It was also found that the Brunauer-Emmett-Teller surface area was increased from 4 m²/g to 49 m²/g after salicylate was intercalated into ZLH. MTT assay revealed that ZnO and SZN 0.8 mol/L had a mild toxic effect on Vero-3 cells, showing a potential for further use in the development of novel inorganic nanoparticle-based drug delivery systems.

**Acknowledgments**

Funding for this research was provided by the Ministry of Science, Technology, and Innovation of Malaysia under a RUGS grant (05-03-10-1035RU). The Universiti Teknologi Malaysia and the Ministry of Higher Education Malaysia are gratefully acknowledged for providing study leave and a scholarship for MR.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


